民族奶粉之光!蒙牛瑞哺恩MLCT+新型OPO临床实证荣登国际知名学术期刊

作者:王碧
昨天

蒙牛始终围绕“消费者第一第一第一”的核心价值观,让消费者喝上奶、喝好奶、喝对奶。这一承诺的分量还在持续攀升。


近日,中国婴配粉又迎来重磅学术突破!蒙牛瑞哺恩母源MLCT1+新型OPO2的临床干预实验成果,荣登国际知名学术期刊《Nutrients》!这不仅彰显了中国奶粉品牌的科研硬实力,更标志着婴配粉加速迈入科研实证的全新纪元。通过前沿技术与严谨实证的深度结合,蒙牛瑞哺恩为中国宝宝带来更科学、更优质的喂养方案,将蒙牛“喝上奶、喝好奶、喝对奶”的品牌承诺转化为实打实的科研成果。



民族奶粉之光

瑞哺恩实证成果荣登国际知名学术期刊


或许有人会问,《Nutrients》究竟是什么来头?它的含金量堪比科研成果的“权威质检站”!


《Nutrients》是由全球知名的MDPI出版社发行的,是JCR营养与膳食领域的1区期刊。在1区期刊上发表的研究成果,往往对整个行业的发展具有重要的引领和示范效应。因此,作为一本国际性的、同行评审的、开放获取的权威期刊,《Nutrients》被SCIE、Scopus、PubMed、MEDLINE等多个国际权威数据库收录,影响力辐射100多个国家和地区。



能被JCR营养与膳食领域1区期刊、全球100多个国家和地区广泛认可的《Nutrients》收录,蒙牛瑞哺恩究竟携怎样惊艳的临床实验成果亮相?又将为奶粉行业带来哪些颠覆性变革?


权威临床试验

瑞哺恩引领婴配粉实证研究新范式


母乳是婴儿的最佳营养来源,也是婴配粉的黄金标准。回看全球婴配粉发展,都是母乳研究助推配方不断迭代。而我国婴配粉因起步较晚,在很大程度上是踩着欧美研发团队走过的路行进着,核心技术也一直由欧美团队掌握。


直至2022年,这一局面被蒙牛瑞哺恩突破性打破。这一年,蒙牛瑞哺恩将母源MLCT1与采用UPU技术制备得到的新型OPO2创新融合,并成功应用于其婴配粉中。这不仅标志着中国乳企冲破西方百年科研封锁与垄断,更标志着乳企在人体三大宏量营养素之一的脂肪研究上取得重大科研进展。


研究显示,中长链甘油三酯(MLCTs)与sn-2棕榈酸酯这对“黄金CP”,约占母乳脂肪总量的70%-80%3堪称婴儿成长的“营养密码”。


其中,母乳中的MLCT由中链与长链脂肪酸酯化而成,占总脂质的20%-40%4, 5。体外消化实验证实,富含MLCT的人乳在肠道消化后表现出更高的脂解率5;添加了MLCT的婴儿配方奶粉与不含MLCT的婴儿配方奶粉相比,脂解程度更高6。MLCT的有效消化和吸收满足了婴儿对高能量的需求,并且与他们尚未成熟的胃肠道系统相兼容7,8


此外,MLCT还被发现可以刺激脂肪组织中的脂肪酸代谢,增强肝脏β-氧化,并抑制内脏脂肪积累,可能促进生长并降低肥胖风险9-12。然而,婴儿配方奶粉通常由中链甘油三酯(MCT)和长链甘油三酯(LCT)的物理混合物组成,这与人乳中的MLCT不同,可能导致不同的脂质消化和代谢4


因此,蒙牛瑞哺恩全球首创母源MLCT1,并将其成功应用于婴配粉产品中,这一创新不仅填补了行业空白,更为提升婴配粉的营养亲和性与吸收效率提供了突破性解决方案,对推动婴配粉配方迭代具有里程碑意义。


而sn-2棕榈酸酯同样大有乾坤。在人乳中,sn-2棕榈酸酯约占总棕榈酸的70~75%。其独特的酯化结构,使棕榈酸牢牢锁定在sn-2位置,不易被轻易分解,这有助于其吸收并减少钙皂的形成13-16,从而支持骨骼健康和婴儿早期生长发育17。此外,sn-2棕榈酸酯与油酸连接在sn-1/3位置,称为1,3-二油酸-2-棕榈酸甘油三酯(OPO),约占人乳中总甘油三酯的15%18, 19。富含sn-2棕榈酸酯的配方奶对生长和胃肠道耐受性有积极影响20-22,包括改善大便质地,以及提高婴儿的舒适度和稳定性23, 24而蒙牛瑞哺恩开发的新型OPO2,就属于sn-2棕榈酸酯。


此次被《Nutrients》收录的临床试验结论显示,含有MLCT和sn-2棕榈酸酯的新型婴儿配方奶安全且耐受良好,支持适当的体重增长并改善脂质吸收。这一关键结论,正是蒙牛瑞哺恩“母源MLCT1+新型OPO2”专利25亲和配方2610大真实喂养效果临床实证的核心成果。



10大实证喂养效果

为中国宝宝带来“吒”实长肉喂养选择


《2024年度奶粉智库公众平台用户问题关键词报告》显示,在宝宝的“生长发育”相关问题中,对于宝宝是否在正常长肉这一维度,家长们的关注度最高,占比达到56.36%;其次是与长肉息息相关的消化吸收,占比20.45%。这背后,是新生代父母“可视化”喂养的需求转变。


而蒙牛瑞哺恩,不仅开创母源MLCT1+新型OPO2,更突破奶粉临床实证塔尖,给消费者带来实实在在的“母源MLCT1+新型OPO2专利25亲和配方2610大真实喂养效果临床实证。


在长肉维度,蒙牛瑞哺恩临床实证显示,相对于喝普通奶粉27的宝宝,使用专利25亲和配方26喂养的宝宝,体重增长比普通奶粉27要高出16%,同时63%的宝宝体重优于同龄的宝宝,有55%的宝宝长高速度优于同龄儿;在消化吸收方面,体内没有消化的甘油三酯减少了42%,没有吸收的游离脂肪酸减少16%,脂肪堆积风险预警指标值下降29%;同时,便便的颜色评分更优28这不仅为万千父母带来看得见的真实喂养效果,也为消费者选择“长肉”奶粉提供了首选。



从全球首创的配方突破,到临床实证的技术跨越,再到国际知名期刊的权威认可,蒙牛瑞哺恩不断以里程碑式成就,书写着国粉的创新传奇。这不仅是蒙牛瑞哺恩“消费者第一第一第一” 核心价值观的生动注脚,更是中国奶粉品牌科研实力崛起的缩影。


注释:

1.母源MLCT:①母源指MLCT营养成分为母乳中存在的营养成分;袁婷兰、韦伟、叶兴旺、刘正冬、闫志远、金青哲、王兴国,母乳中长链甘油三酯研究进展,食品与生物技术学(J],2022.41(6):41-50;②MLCT来源于中长链脂肪酸食用油.

2.OPO:1.3-二油酸2-棕榈酸甘油三酯.

3.Xiaoyan Chen, Mengtao Yang, Wei Wei, et al. A Novel Infant Formula with Medium- and Long-Chain Triacylglycerols and sn-2 Palmitate Supports Adequate Growth and Lipid Absorption in Healthy Term Infants[J]. Nutrients, 2025, 17(9), 1401.

4.Cheng, X.; Jiang, C.; Jin, J.; Jin, Q.; Akoh, C.C.; Wei, W.; Wang, X. Medium- and Long-Chain Triacylglycerol: Preparation, Health Benefits, and Food Utilization. Annu. Rev. Food Sci. Technol. 2024, 15, 381–408.

5.Yuan, T.; Geng, Z.; Dai, X.; Zhang, X.; Wei, W.; Wang, X.; Jin, Q. Triacylglycerol Containing Medium-Chain Fatty Acids: Comparison of Human Milk and Infant Formulas on Lipolysis during In Vitro Digestion. J. Agric. Food Chem. 2020, 68, 4187–4195.

6.Wang, L.; Zhang, X.; Yuan, T.; Jin, Q.; Wei, W.; Wang, X. Digestion of Medium- and Long-Chain Triacylglycerol and sn-2 Palmitate in Infant Formula: A Study Based on Dynamic In Vitro Simulation of Infant Gastrointestinal Lipolysis. J. Agric. Food Chem. 2022, 70, 3263–3271.

7.Jensen, C.; Fau Buist, N.R.; Wilson, T. Absorption of individual fatty acids from long chain or medium chain triglycerides in very small infants. Am. J. Clin. Nutr. 1986, 43, 745–751.

8.Nejrup, R.G.; Licht, T.A.-O.; Hellgren, L.A.-O. Fatty acid composition and phospholipid types used in infant formulas modifies the establishment of human gut bacteria in germ-free mice. Sci. Rep. 2017, 7, 3975.

9.Shinohara, H.; Wu, J.; Kasai, M.; Aoyama, T. Randomly interesterified triacylglycerol containing medium- and long-chain fatty acids stimulates fatty acid metabolism in white adipose tissue of rats. Biosci. Biotechnol. Biochem. 2006, 70, 2919–2926.

10.Lee, Y.Y.; Tang, T.K.; Phuah, E.T.; Karim, N.A.A.; Alitheen, N.B.M.; Tan, C.P.; Razak, I.S.A.; Lai, O.M. Structural difference of palm based Medium- and Long-Chain Triacylglycerol (MLCT) further reduces body fat accumulation in DIO C57BL/6J mice when consumed in low fat diet for a mid-term period. Food Res. Int. 2018, 103, 200–207.

11.Du, Y.X.; Chen, S.N.; Zhu, H.L.; Niu, X.; Li, J.; Fan, Y.W.; Deng, Z.Y. Consumption of Interesterified Medium- and Long-Chain Triacylglycerols Improves Lipid Metabolism and Reduces Inflammation in High-Fat Diet-Induced Obese Rats. J. Agric. Food Chem. 2020, 68, 8255–8262.

12.Tsuji, H.; Kasai, M.; Takeuchi, H.; Nakamura, M.; Okazaki, M.; Kondo, K. Dietary medium-chain triacylglycerols suppress accumulation of body fat in a double-blind, controlled trial in healthy men and women. J. Nutr. 2001, 131, 2853–2859.

13.Bar-Yoseph, F.; Lifshitz, Y.; Cohen, T.; Malard, P.; Xu, C. SN2-Palmitate Reduces Fatty Acid Excretion in Chinese Formula-fed Infants. J. Pediatr. Gastroenterol. Nutr. 2016, 62, 341–347. [Google Scholar] [CrossRef]

14.Innis, S.M. Dietary triacylglycerol structure and its role in infant nutrition. Adv. Nutr. 2011, 2, 275–283. [Google Scholar] [CrossRef]

15.Innis, S.M.; Dyer, R.; Nelson, C.M. Evidence that palmitic acid is absorbed as sn-2 monoacylglycerol from human milk by breast-fed infants. Lipids 1994, 29, 541–545. [Google Scholar] [CrossRef]

16.Shoji, H.A.-O.; Arai, H.A.-O.; Kakiuchi, S.; Ito, A.; Sato, K.A.-O.; Jinno, S.A.-O.; Takahashi, N.A.-O.; Masumoto, K.; Yoda, H.; Shimizu, T. Infant Formula with 50% or More of Palmitic Acid Bound to the sn-2 Position of Triacylglycerols Eliminate the Association between Formula-Feeding and the Increase of Fecal Palmitic Acid Levels in Newborns: An Exploratory Study. Nutrients 2024, 16, 1558.

17.Litmanovitz, I.; Davidson, K.; Eliakim, A.; Regev, R.H.; Dolfin, T.; Arnon, S.; Bar-Yoseph, F.; Goren, A.; Lifshitz, Y.; Nemet, D. High Beta-palmitate formula and bone strength in term infants: A randomized, double-blind, controlled trial. Calcif. Tissue Int. 2013, 92, 35–41.

18.Yu, J.; Yan, Z.; Mi, L.; Wang, L.; Liu, Z.; Ye, X.; Jin, Q.; Pang, J.; Wei, W.; Wang, X. Medium- and long-chain triacylglycerols and di-unsaturated fatty acyl-palmitoyl-glycerols in Chinese human milk: Association with region during the lactation. Front. Nutr. 2022, 9, 1040321.

19.Ghide, M.K.; Li, K.; Wang, J.; Abdulmalek, S.A.; Yan, Y. Immobilization of Rhizomucor miehei lipase on magnetic multiwalled carbon nanotubes towards the synthesis of structured lipids rich in sn-2 palmitic acid and sn-1,3 oleic acid (OPO) for infant formula use. Food Chem. 2022, 390, 133171.

20.Guo, D.; Li, F.; Zhao, J.A.-O.; Zhang, H.A.-O.; Liu, B.; Pan, J.; Zhang, W.; Chen, W.A.-O.; Xu, Y.; Jiang, S.; et al. Effect of an infant formula containing sn-2 palmitate on fecal microbiota and metabolome profiles of healthy term infants: A randomized, double-blind, parallel, controlled study. Food Funct. 2022, 13, 2003–2018.

21.Sheng, X.Y.; Mi, W.; Yuan, Q.B.; Liu, B.Y.; Carnielli, V.; Ning, Y.B.; Einerhand, A.W.C. An A2 β-casein infant formula with high sn-2 palmitate and casein phosphopeptides supports adequate growth, improved stool consistency, and bone strength in healthy, term Chinese infants: A randomized, double-blind, controlled clinical trial. Front. Nutr. 2024, 11, 1442584. [Google Scholar] [CrossRef]

22.Chen, B.; Jia, Q.; Chen, Z.; You, Y.; Liu, Y.; Zhao, J.; Chen, L.; Ma, D.; Xing, Y. Comparative evaluation of enriched formula milk powder with OPO and MFGM vs. breastfeeding and regular formula milk powder in full-term infants: A comprehensive study on gut microbiota, neurodevelopment, and growth. Food Funct. 2024, 15, 1417–1430. [Google Scholar] [CrossRef]

23.Litmanovitz, I.; Bar-Yoseph, F.; Lifshitz, Y.; Davidson, K.; Eliakim, A.; Regev, R.H.; Nemet, D. Reduced crying in term infants fed high beta-palmitate formula: A double-blind randomized clinical trial. BMC Pediatr. 2014, 14, 152. [Google Scholar] [CrossRef]

24.Savino, F.; Palumeri, E.; Castagno, E.; Cresi, F.; Dalmasso, P.; Cavallo, F.; Oggero, R. Reduction of crying episodes owing to infantile colic: A randomized controlled study on the efficacy of a new infant formula. Eur. J. Clin. Nutr. 2006, 60, 1304–1310.

25.中国发明专利,专利号:ZL202110901955

26.亲和配方指代MLCT结构脂+新型OPO.

27.指对比雅士利不含MLCT和OPO组合的配方奶粉.

28.指含MLCT和OPO配方粉的临床喂养研究.

来自:婴童智库
分享
0
相关文章
我要评价
文明上网,理性发言
用户评论
小程序
个人中心
意见反馈